2006 archivos - Histopat laboratoris

Genetic alterations of the epidermal growth factor receptor pathway in a series of non-small cell lung cancer characterized by morphology and immunophenotype

Verdú M,¹ Colomer A,¹ Erill N,¹ Roman R,² Górriz M, ^1,2Ibáñez R,¹ Cordon-Cardo C,¹ Puig X.^1,2

¹HISTOPAT Laboratoris, Barcelona, Catalonia, Spain &²BIOPAT. Biopatologia Molecular, Grup Assistència.

Background: Non-small cell lung cancer (NSCLC) is classified in two main categories: adenocarcinoma (AC), which includes bronchioloalveolar carcinoma (BAC), and squamous cell carcinoma (SCC). Activating mutations and increased copy number of the EGFR gene have been reported in tumors from patients with NSCLC with increased response rate to tyrosine kinase inhibitors (TKIs). There is […]

Alberto 2006-09-23T17:54:01+00:00

A population study on the UGT1A1*28 variant associated to Irinotecan tolerance

Roman R,¹ Colomer A,¹ Erill N,¹ Verdú M,² Ibáñez R,¹ Cordon-Cardo C,¹ Puig X.^1,2

¹BIOPAT. Biopatologia Molecular, Grup Assistència & ²HISTOPAT Laboratoris, Barcelona, Catalonia, Spain.

Background: Irinotecan (CPT-11) is currently used as first- or second-line treatment for colorectal cancer, either alone or in combination with 5-fluorouracil based regimens. UDP-glucuronosyltransferase 1A1 (UGT1A1) catalyzes the inactivation of SN-38, the active metabolite of irinotecan, through glucuronidation. UGT1A1*28, a polymorphic variant of this enzyme displaying an additional TA dinucleotide in the promoter TATA box, has been […]

Alberto 2006-09-23T17:11:42+00:00

Epidermal growth factor receptor in non small cell lung cancer: Gene copy number and mutational study

Colomer A, Erill N, Verdú M, Román R, Górriz M, Ibáñez R, Menoyo A, Cordon-Cardo C, Puig X.

^{BIOPAT, Grup Assistència, HISTOPAT Laboratoris, Barcelona, Spain; and Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York, United States.}

Background: Activating mutations of the EGFR gene were identified in tumors from patients with non small cell lung cancer (NSCLC) that responded to therapy with tyrosine kinase inhibitors (TKIs). More recently, survival has been reported to significantly increase amongst patients carrying a […]

Alberto 2006-02-23T17:52:21+00:00